Stock Market Reviews

CMPX (Compass Therapeutics, Inc.) News

Get the latest news, insights, and market updates on CMPX (Compass Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted non-qualified stock options to purchase 1,000,
  Jan 5, 2026 - $CMPX
• Compass Therapeutics Announces Key Leadership Appointments
  BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. “We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished l
  Jan 5, 2026 - $CMPX
• Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment
  Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 12 best multibagger stocks to buy heading into 2026. On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price target. The analyst attributed the bullish stance to positive data in the […]
  Dec 21, 2025 - $CMPX
• Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
  Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
  Dec 19, 2025 - $CMPX
• Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
  BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability: The presentation will be archived on Compass’ Events pag
  Dec 17, 2025 - $CMPX
• Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
  The consensus price target hints at a 134.1% upside potential for Compass Therapeutics, Inc. (CMPX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
  Dec 12, 2025 - $CMPX
• Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
  Does Compass Therapeutics, Inc. (CMPX) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Dec 8, 2025 - $CMPX
• Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
  Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up ... Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
  Dec 3, 2025 - $CMPX
• Compass Therapeutics (CMPX) Is Up 17.2% After Analyst Highlights Pipeline Progress and Anticipated Tovecimig Data – Has the Bull Case Changed?
  On November 10, 2025, H.C. Wainwright reiterated its positive view on Compass Therapeutics, highlighting encouraging preclinical progress for CTX-10726 and reporting favorable initial results for CTX-8371 in the company's advancing oncology pipeline. The company expects pivotal survival data for tovecimig in late Q1 2026, which could support its first biologics license application filing in the second half of next year. We'll examine how analyst optimism around Compass Therapeutics’ clinical...
  Dec 1, 2025 - $CMPX
• A Look at Compass Therapeutics (CMPX) Valuation Following Strong CTX-10726 Preclinical Data and Management Update
  Compass Therapeutics (CMPX) drew fresh attention after preclinical data for CTX-10726 were presented at SITC 2025. The data highlighted anti-tumor activity and a distinct profile compared to similar agents. Company management also reaffirmed upcoming clinical milestones for tovecimig, adding to recent investor interest. See our latest analysis for Compass Therapeutics. Compass Therapeutics’ share price momentum has been nothing short of impressive, surging 314% year-to-date with a 255% total...
  Dec 1, 2025 - $CMPX